[Body composition and metabolic risk in small for gestational age children treated with growth hormone]

Med Clin (Barc). 2016 Sep 16;147(6):231-7. doi: 10.1016/j.medcli.2016.06.002. Epub 2016 Jul 14.
[Article in Spanish]

Abstract

Background and objectives: Small for gestational age (SGA) children are at increased risk of metabolic syndrome. Our objective is to evaluate changes in body composition produced by growth hormone (GH) treatment.

Patients and method: A group of 28 SGA children without catch-up growth and undergoing treatment with GH was selected for evaluation. Over the course of 3 years from the beginning of the treatment with GH, the children's body composition variables (bone mineral density [BMD], fat and lean body mass proportion) were evaluated annually with dual-energy X-ray absorptiometry. A study of correlation between metabolic and body composition variables was also made.

Results: Treatment with GH produces a reduction in fat mass proportion in relation to lean body mass, decreasing from 25.94±6.09 to 22.88±5.38% (P=.034). In the abdominal regions we observe an increase in lean mass, from 1,356,91±426,71 to 2,570,96±814,36g (P=.000) and a tendency for visceral fat deposits to decrease. BMD in lumbar vertebrae improved from -1.55±0.68 to -0.90±0.79Z (P=.019).

Conclusions: Treatment with GH produces changes in body composition, improving BMD and increasing the proportion of lean body mass with a reduction in fat mass. If these changes persisted into adulthood, they may cause a reduction in the metabolic and cardiovascular risk in this group of patients.

Keywords: Birth weight; Body composition; Body fat; Bone mineral content; Composición corporal; Contenido mineral óseo; Grasa corporal; Peso al nacer.

Publication types

  • Clinical Trial

MeSH terms

  • Absorptiometry, Photon
  • Body Composition / drug effects*
  • Bone Density / drug effects*
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Child
  • Child, Preschool
  • Female
  • Growth Disorders / complications
  • Growth Disorders / drug therapy*
  • Growth Disorders / metabolism
  • Growth Disorders / pathology
  • Growth Hormone / pharmacology
  • Growth Hormone / therapeutic use*
  • Humans
  • Infant, Small for Gestational Age*
  • Longitudinal Studies
  • Male
  • Metabolic Syndrome / etiology
  • Metabolic Syndrome / prevention & control*
  • Prospective Studies
  • Risk Factors
  • Treatment Outcome

Substances

  • Growth Hormone